Filing Flows

Filing Flows › Health Care › Twist Bioscience (TWST)

Twist Bioscience (TWST) earnings and revenue breakdown

Latest: Q3 FY26 · 10-Q filed Aug 3, 2026 · Twist Bioscience (TWST) Q3 FY26 earnings results →

Q3 FY26 Revenue up 23% year over year to $118M · 30¢ of every $1 of revenue lost · operating margin -30.6%

Twist Bioscience made $118M in Q3 FY26 (+23% Y/Y): NGS applications $61.8M, DNA synthesis and protein solutions $56.6M. Operating margin -30.6%, net loss $35.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 3, 2026.

Revenue$118M
Year over year+23%
Operating margin-30.6%
Net earnings−$35.1M
Operating cash flow$1.1M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $118.4M in Q3 FY26, up 23% year over year and up 7% from the previous quarter. NGS applications was the largest line at 52% of revenue. DNA synthesis and protein solutions added $15.8M year over year (up 39%), 71% of the total change.

Operating costs exceeded revenue by $36.3M, an operating margin of -30.6%. Total costs grew 23% against revenue growth of 23%. The fastest-growing cost line was SG&A (+27%). The quarter ended with a net loss of $35.1M, narrower than the previous quarter's $44.0M loss.

Operating cash flow was $1.1M. Non-cash charges added back $6.8M of depreciation and amortization and $18.2M of share-based compensation. Working capital and other items added $11.2M. Capital expenditures of $9.8M exceeded it, leaving free cash flow of −$8.6M.

Quarterly history

Twist Bioscience revenue by quarterTwist Bioscience revenue by quarter$84.7MQ4 FY24$92.8MQ2 FY25$96.1MQ3 FY25$99.0MQ4 FY25$104MQ1 FY26$111MQ2 FY26$118MQ3 FY26
Twist Bioscience net earnings by quarterTwist Bioscience net earnings by quarter−$34.7MQ4 FY24−$39.3MQ2 FY25$20.4MQ3 FY25−$27.1MQ4 FY25−$30.5MQ1 FY26−$44.0MQ2 FY26−$35.1MQ3 FY26
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q3 FY2610-QAug 3, 2026$118M+23%-30.6%−$35.1M$1.1M
Q2 FY2610-QMay 4, 2026$111M+19%-41.4%−$44.0M−$17.6M
Q1 FY2610-QFeb 2, 2026$104M+17%-31.7%−$30.5M−$24.8M
Q4 FY2510-KNov 17, 2025$99.0M+17%-30.2%−$27.1M−$11.8M
Q3 FY2510-QAug 4, 2025$96.1M+18%-31.4%$20.4M−$1.4M
Q2 FY2510-QMay 5, 2025$92.8M+23%-44.8%−$39.3M−$13.0M
Q4 FY2410-KNov 18, 2024$84.7M+26%-42.5%−$34.7M−$15.3M

Charts

Twist Bioscience: revenue growth, year over year and quarter over quarterTwist Bioscience: revenue growth, year over year and quarter over quarterY/YQ/Q+26%Q4 FY24+23%+10%Q2 FY25+18%+4%Q3 FY25+17%+3%Q4 FY25+17%+5%Q1 FY26+19%+7%Q2 FY26+23%+7%Q3 FY26
Latest (Q3 FY26): Y/Y +23%, Q/Q +7%.
Twist Bioscience: where the cash came from (+) and went (−), TTM to Q3 FY26Twist Bioscience: where the cash came from (+) and went (−), TTM to Q3 FY26Cash drawn (+) / kept (−)$84.3MOperating cash flow−$53.1MCapital spending−$40.1MShares issued$9.7MOther investing−$5.2MOther financing$4.1MExchange rates$176K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Twist Bioscience: profit against cash, quarter by quarterTwist Bioscience: profit against cash, quarter by quarterNet incomeOperating cash flow−$34.7M−$15.3MQ4 FY24−$31.6M−$21.4MQ1 FY25−$39.3M−$13.0MQ2 FY25$20.4M−$1.4MQ3 FY25−$27.1M−$11.8MQ4 FY25−$30.5M−$24.8MQ1 FY26−$44.0M−$17.6MQ2 FY26−$35.1M$1.1MQ3 FY26
Latest (Q3 FY26): Net income −$35.1M, Operating cash flow $1.1M.
Twist Bioscience: diluted shares by fiscal yearTwist Bioscience: diluted shares by fiscal year39MFY2048MFY2154MFY2257MFY2358MFY2460MFY25
+52.6% since FY20: more shares outstanding (issuance, stock pay).
Twist Bioscience in its industry: growth against margin (76 companies, SIC 2836)Twist Bioscience in its industry: growth against margin (76 companies, SIC 2836)revenue growth, year over year →↑ operating marginmedian +9%median -100%AMGNGILDBIIBMRNANBIXEXELHALOMGTXTECHVIRRGENTARSBCRXALECADMAKRYSIOVAIPSCIMCRVISKVCELADPTNVAXKYMRGLUEIBRXAUTLAGENDNAPLXRXRXFENCCSBRCHRSIVVDCRSPEDITDTILVXRTSTRORGNXCCCCBSEMSCLXACOGTSHASRZNVYGRFDMTLENZALGSXFORELUTFATEOCGNSCTXCRBUCGONDBVTINBXMGXLCTXTCRXDYAIPRMEATRAVitro Biopharma, Inc.HUMARLAYPLURBEAMPROKCRDFAIMVIVSTWST (+23%, -31%)
Biological Products, (No Diagnostic Substances); dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

Customers and suppliers named in filings

Sells to

About Twist Bioscience

At Twist Bioscience Corporation, we work in service of our customers who are changing the world for the better. In fields such as health care, food/agriculture, industrial chemicals/materials and academic research, by using our products, our customers are developing ways to better lives and improve the sustainability of the planet. We believe Twist Bioscience is uniquely positioned to help accelerate their efforts and the faster our customers succeed, the better for all of us. We have developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip.

In its own words, from its 10-K, filed Nov 17, 2025.

Twist Bioscience against its Biological Products, (No Diagnostic Substances) peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +23% against the peers' median +23%. Operating margin: -30.6% against the peers' median 35.8%.

CompanyQuarterRevenueY/YOp. margin
TWST Twist BioscienceQ3 FY26$118M+23%-30.6%
AMGN AmgenQ3 2026$10.4B+8%35.8%
GILD Gilead SciencesQ3 2026$8.3B+7%41.7%
BIIB BiogenQ3 2026$2.8B+11%-0.3%
MRNA ModernaQ3 2026$1.3B+29%9.9%
NBIX Neurocrine BiosciencesQ3 2026$1.1B+41%29.5%
EXEL ExelixisQ3 2026$659M+10%40.8%
HALO Halozyme TherapeuticsQ3 2026$493M+39%59.8%
MGTX MeiraGTx HoldingsQ2 2026$321M87×76.0%

Source: Twist Bioscience 10-Q on SEC EDGAR · CIK 1581280 · Biological Products, (No Diagnostic Substances)

Guidance and outlook

Twist Bioscience Revenue: guidance against what was reportedTwist Bioscience Revenue: guidance against what was reportedguided rangereported (above / within / below)FY24$313MQ4 FY24$84.7MQ1 FY25FY25$377MFY26Q1 FY26$104MQ3 FY26$118MQ4 FY26
Met or beat 5 of 5 guided periods. Grey: the last range guided before the figures came out; dot: the reported figure.

13F: who owns TWST and who is buying

Largest holders of TWST (13F)Largest holders of TWST (13F)BlackRock$600MArtisan Partners Limited Partners…$494MFMR LLC$484MARK Investment Management LLC$468MPrice T Rowe Associates$374MState Street$333MVanguard Portfolio Management LLC$291MVanguard Capital Management LLC$278MEdgePoint Investment Group$259MWilliam Blair Investment Manageme…$224M
Funds' net buying of TWST by quarter (13F)Funds' net buying of TWST by quarter (13F)−$43.0M2024-09$20.5M2024-12$130M2025-03$55.2M2025-06$85.6M2025-09$61.6M2025-12$35.2M2026-03−$167M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on TWST

History

Every quarter: Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results · Q2 FY25 results · Q4 FY24 results

Compare TWST with

中文版：Twist Bioscience（TWST）财报

Español · Français